Contents Vol. 34, Supplement 3, 1987

List of Contributors

Foreword

Introductory Lecture

1-6    L. Hansson and J.I.S. Robertson
       Is Hypertension Treated Adequately?

Section 1: Pharmacology and Human Pharmacokinetics of Felodipine

7-15   B. Ljung and M. Nordlander
       Pharmacodynamic Properties of Felodipine

16-27  B. Edgar, P. Lundborg and C.G. Regårdh
       Clinical Pharmacokinetics of Felodipine: A Summary

Poster Presentations

28-29  B. Edgar, P. Collste, K. Haglund and C.G. Regårdh
       Pharmacokinetics and Haemodynamics of Felodipine as Monotherapy in Hypertensive
       Patients (Short Communication)

30     D. Elmfeldt, B. Bengtsson, B. Edgar, L. Moberg and O. Rönn
       Pharmacokinetics and Haemodynamics of Felodipine in Hypertensive Patients Treated
       Concomitantly with a β-Blocker (Short Communication)

31-32  B. Edgar, M. Aurell, G. Johnsson, C.G. Regårdh and C. Shansky
       Effects of Impaired Renal Function on the Pharmacokinetics of Felodipine (Short
       Communication)

33-42  N. Rehnqvist, E. Billing, L. Moberg, T. Lundman and G. Olsson
       Pharmacokinetics of Felodipine and Effect on Digoxin Plasma Levels in Patients
       with Heart Failure

43-52  K.-J. Hoffmann and L. Andersson
       Metabolism of [14C] Felodipine, a New Vasodilating Drug, in Healthy Volunteers
53-56  M. Nordlander, R. Horton and P. Thalen
Baroreflex Control of Renin Release in Spontaneously Hypertensive Rats after
Administration of Felodipine

57-58  Poster Discussion: Section 1

Section 2: Renal and Cardiac Effects of Felodipine

59-66  G. Leonetti, L. Terzoli, L. Rupoli, R. Gradnik and A. Zanchetti
Renal Effects of Felodipine in Hypertension

67-68  U.L. Hulthen, P.L. Katzman and B. Hökfelt
Effect of Long Term Felodipine Treatment on Renal Vascular Tone, Glomerular Filtration
Rate and Renal Tubular Function in Essential Hypertension (Short Communication)

69-70  E. Kassis, S. Waldorff and O. Amtorp
Haemodynamic Effects of Felodipine during Supine Resting and Exercising States and
Orthostatic Tilt in Patients with Chronic Congestive Heart Failure (Short Communication)

71-78  J.V. Sheridan, P. Thomas and D.J. Sheridan
Felodipine in Ischaemic Heart Disease

Poster Presentations

79-80  P.H.J.M. Dunselman, C.E.E. Kuntze, A. van Bruggen and Kong I. Lie
Felodipine in Heart Failure: A Double-Blind, Randomised, Placebo-Controlled Parallel-
Group Study in 23 Patients (Short Communication)

81-84  P. Held and K. Swedberg
Haemodynamic Effects of Felodipine in Congestive Heart Failure

85-86  A.J. Drake-Holland, S. Pugh, C. Mills and M.I.M. Noble
The Effects of Felodipine on Left Ventricular Function in β-Blocked Patients

87-92  B. Jackson, B.P. McGrath and C.I. Johnston
Hormonal and Blood Pressure Responses to Tilting in β-Blocked Essential Hypertension
Treated with Felodipine or Prazosin

93-94  P.L. Katzman, U.L. Hulthen and B. Hökfelt
Glucose Tolerance and Secretion and Clearance of Insulin during Long Term Felodipine
Treatment (Short Communication)

95-96  Poster Discussion: Section 2

Section 3: Felodipine in Hypertension

97-106  H.E. Sluiter (on behalf of the Dutch Multicentre Study Group)
Felodipine in Hypertensive Patients: A Dose Finding Study in Patients Refractory to
β-Blocker Monotherapy
Contents

107-108  W.A. Littler, S.A. Smith and P.J.E. Mace
Felodipine Monotherapy in Hypertension (Short Communication)

109-119  B. Jackson, T.O. Morgan, J. Gibson and A. Anderson
Felodipine versus Prazosin as an Addition to a β-Blocker in the Treatment of Essential Hypertension: The Australian Multicentre Study

120-124  A.L. Muir and C.G. Wathen
The Use of Felodipine in the Treatment of Severe Hypertension

125-131  T. Hedner, D. Elmfeldt, C. Dahlof and E. Sjögren
Comparison of Antihypertensive Effect and Pharmacokinetics of Conventional and Extended Release Felodipine Tablets in Patients with Arterial Hypertension

132-135  D. Elmfeldt and S. Westerling
Aspects on the Benefit-Risk Balance of Felodipine in Hypertension

Poster Presentations

Felodipine versus Hydrochlorothiazide as an Addition to a β-Blocker in the Treatment of Hypertension (Short Communication)

139-148  Cooperative Study Group
Felodipine, a New Calcium Antagonist, as Monotherapy in Mild or Moderate Hypertension

Hypertension in the Elderly: Its Diagnosis in General Practice and Treatment with Felodipine and Metoprolol (Short Communication)

151-155  H. Herlitz, S. Björck, G. Nyberg, G. Granérus and M. Aurell
Clinical Evaluation of Felodipine in Patients with Refractory Hypertension

156-160  O.K. Andersson, T. Hedner and G. Granérus
Felodipine in Combination with a β-Blocker and a Diuretic in Chronic Treatment of Patients with Refractory Primary Hypertension

161  T. Hedner (on behalf of the Swedish Multicentre Study Group)
Clinical Evaluation of Felodipine in Hypertensive Patients Previously Treated with a Triple Drug Regimen

162-169  B. Krönig and G. Flygt
Felodipine versus Moduretic®: A Double-Blind Parallel-Group Multicentre Study

170-175  P. Lijnen, R. Fagard, J. Staessen, E. Moerman, A. De Schaeppdryver and A. Amery
Effects of Felodipine and Metoprolol on Blood Pressure, Plasma Renin, Angiotensin II, Aldosterone and Catecholamines in Hypertensive Patients
176-177  **Canadian Felodipine Study Group**  
A Dose-Response Study of Felodipine in Patients Remaining Hypertensive on a β-Blocker  
(Short Communication)

Short and Long Term Treatment of Essential Hypertension with Felodipine as Monotherapy

186-193  **H.E. Sluiter, F.Th.M. Huysmans, Th.A. Thien and R.A.P. Koene**  
Antihypertensive and Biochemical Effects of the Dihydropyridine Felodipine in the Long  
Term Treatment of Moderate to Severe Hypertension

194-197  **L.M.H. Wing, J.P. Chalmers, M.J. West, A.J.C. Bune and A.E. Russell**  
Felodipine Monotherapy in Systolic Hypertension in the Elderly

198-202  **Poster Discussion: Section 3**

203-209  **Panel Discussion**